Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 19, 2007. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, executed under authority granted by shareholders at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the share repurchase transaction:
- Shares Purchased: 450,000 ordinary shares of 25 pence each.
- Purchase Price: 1,475.0173 pence per share.
- Transaction Date: April 19, 2007.
Material Changes
Following the repurchase, the company's Treasury share holdings increased to 287,792,678 shares. The total number of shares in issue (excluding Treasury shares) stands at 5,728,073,846. This figure represents the total voting rights and serves as the denominator for shareholder notification calculations under the Financial Services Authority's Disclosure and Transparency Rules.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Transparency Directive's transitional provision 6.
Investor Verification Checklist
- Verify the total number of shares in issue (5,728,073,846) for accurate calculation of ownership thresholds.
- Confirm the updated Treasury share count (287,792,678) for capital structure analysis.
- Note that this filing is a routine disclosure of a share buyback and does not contain operational or financial performance data.